But WeightWatchers is offering a new GLP-1 drug called Sequence

Oprah Winfrey announced she would not stand for re-election on the WeightWatchers Board of Directions due to a perceived conflict of interest around her taking a weight loss medication. The announcement sent the company’s stock tumbling. Winfrey has served on WeightWatchers since 2015. 

Healthline, a publication, reports Oprah takes GLP-1 medications to manage her weight and says she’s hoping her story can help lessen the stigma about taking such drugs.

Winfrey recently shared that she is taking a weight loss drug but did not specify which one. WeightWatchers Clinic offers Sequence, an integrated GIB-1 program that reduces weight. The drug is injected into a person’s arm and can be self-administered.

Drugs like Ozempic and Wegovy, which were introduced to help people with diabetes, have soared in popularity in recent years because they are also used to help consumers lose weight. 

Oprah said she was gone but not leaving.

 “I look forward to continuing to advise and collaborate with WeightWatchers and CEO Sima Sistani in elevating the conversation around recognizing obesity as a chronic condition, working to reduce stigma, and advocating for health equity,” said Oprah Winfrey.

WeightWatchers shares plunged by 25% in premarket trading Thursday and are down nearly 70%.